

Alessandra Gennari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2839524/publications.pdf>

Version: 2024-02-01

108
papers

6,512
citations

101543

36
h-index

66911

78
g-index

113
all docs

113
docs citations

113
times ranked

9390
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast Cancer Diet "BCD": A Review of Healthy Dietary Patterns to Prevent Breast Cancer Recurrence and Reduce Mortality. <i>Nutrients</i> , 2022, 14, 476.	4.1	14
2	Definition of High-Risk Early Hormone-Positive HER2~Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
3	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
4	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	2.8	11
5	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	2.8	19
6	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	10.7	50
7	Implications of metabolism-driven myeloid dysfunctions in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 829-841.	10.5	21
8	Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast Cancer. <i>Breast Care</i> , 2021, 16, 299-306.	1.4	2
9	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	3.2	4
10	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2137.	3.7	11
11	Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19. <i>Disease Markers</i> , 2021, 2021, 1-7.	1.3	24
12	A randomized clinical study on the impact of Comprehensive Geriatric Assessment (CGA) based interventions on the quality of life of elderly, frail, onco-hematologic patients candidate to anticancer therapy: protocol of the ONCO-Aging study. <i>BMC Geriatrics</i> , 2021, 21, 320.	2.7	5
13	Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12038-12038.	1.6	2
14	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	2.8	37
15	SARS~CoV~2 reinfection in a cancer patient with a defective neutralizing humoral response. <i>Journal of Medical Virology</i> , 2021, 93, 6444-6446.	5.0	10
16	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	2.6	19
17	Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. <i>European Journal of Cancer</i> , 2021, 155, 127-135.	2.8	3
18	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12

#	ARTICLE	IF	CITATIONS
19	Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. <i>Biomolecules</i> , 2021, 11, 125.	4.0	27
20	Metastatic Mediastinal Germâ€Cell Tumor and Concurrent COVID â€19: When Chemotherapy Is Not Deferrable. <i>Oncologist</i> , 2021, 26, e347-e349.	3.7	3
21	Precision Medicine in Systemic Mastocytosis. <i>Medicina (Lithuania)</i> , 2021, 57, 1135.	2.0	4
22	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	10.7	73
23	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
24	ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study. <i>Frontiers in Medicine</i> , 2021, 8, 817678.	2.6	1
25	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	3.7	58
26	Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 20731.	3.3	96
27	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 556718.	2.8	49
28	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	9.4	151
29	Breast Cancer Survivorship, Quality of Life, and Late Toxicities. <i>Frontiers in Oncology</i> , 2020, 10, 864.	2.8	121
30	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 61-68.	2.5	15
31	Oncolytic virotherapy: new weapon for breast cancer treatment. <i>Ecancermedalscience</i> , 2020, 14, 1149.	1.1	12
32	PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: A pooled analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15263-e15263.	1.6	0
33	Helping the cardio-oncologist: from real life to guidelines. <i>Seminars in Oncology</i> , 2019, 46, 433-436.	2.2	1
34	Phase II Study of Dehydroepiandrosterone in Androgen Receptorâ€Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, 743.	3.7	7
35	Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 433-442.	2.5	77
36	Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. <i>Cell Stress</i> , 2019, 3, 284-294.	3.2	40

#	ARTICLE	IF	CITATIONS
37	Host metabolic factors and prognosis in patients treated with immune checkpoint inhibitors for advanced malignancies.. Journal of Clinical Oncology, 2019, 37, e14162-e14162.	1.6	0
38	A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Annals of Oncology, 2018, 29, 661-668.	1.2	11
39	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 127-138.	10.7	91
40	Efficacy of CDK 4/6 inhibitors in ER positive metastatic breast cancer: Systematic review and meta-analysis of randomized clinical trials.. Journal of Clinical Oncology, 2018, 36, e13040-e13040.	1.6	1
41	3rd ESOâ€“ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 2017, 28, 16-33.	1.2	865
42	3rd ESOâ€“ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, 244-259.	2.2	171
43	Editorial: Why are guidelines not followed in clinical practice?. Breast, 2017, 32, 245-246.	2.2	5
44	Association between insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) and prognosis in patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2017, 35, 1086-1086.	1.6	13
45	Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. Translational Oncology, 2016, 9, 600-605.	3.7	11
46	Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials. Clinical Cancer Research, 2016, 22, 4594-4603.	7.0	32
47	Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treatment Communications, 2016, 6, S1-S10.	0.4	10
48	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. Breast Cancer Research and Treatment, 2016, 159, 79-86.	2.5	20
49	ERA-Net TRANSCAN JTC 2011: Critical aspects of the startup procedures of an International Academic Clinical trial (ET-FES), funded by the European Community (EC) and coordinated by an Italian Institution.. Annals of Oncology, 2016, 27, iv113.	1.2	1
50	Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials. Annals of Oncology, 2016, 27, vi61.	1.2	0
51	Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine, 2016, 14, 1.	5.5	521
52	Ovarian stimulation for infertility treatment and cancer risk: An Italian cohort study.. Journal of Clinical Oncology, 2016, 34, 534-534.	1.6	0
53	News from the San Antonio Breast Cancer Symposium 2014. Breast Care, 2015, 10, 61-64.	1.4	0
54	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies. Breast Cancer Research and Treatment, 2015, 150, 405-413.	2.5	38

#	ARTICLE	IF	CITATIONS
55	IN28 DURATION OF FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER. <i>Breast</i> , 2015, 24, S31.	2.2	0
56	BP129 INSULIN RESISTANCE (IR) AND PROGNOSIS OF METASTATIC BREAST CANCER (MBC) PATIENTS. <i>Breast</i> , 2015, 24, S66.	2.2	0
57	18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. <i>Nuklearmedizin - NuclearMedicine</i> , 2015, 54, 163-172.	0.7	18
58	Breast cancer incidence after hormonal treatments for infertility: Systematic review update.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11552-e11552.	1.6	0
59	Abstract 1182: Metformin affects breast cancer cell growth and disturbs an IGF1/insulin related gene network that correlates with breast cancer progression. <i>Cancer Research</i> , 2015, 75, 1182-1182.	0.9	0
60	An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1437-1442.	2.4	11
61	Impact of insulin resistance (IR) on the prognosis of metastatic breast cancer (MBC) patients treated with first-line chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 514-514.	1.6	1
62	The Role of Liposomal Anthracyclines in Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 23-30.	1.0	0
63	Anthracycline-free therapy for HER2 -amplified breast cancer. <i>Lancet Oncology, The</i> , 2013, 14, 1037-1038.	10.7	1
64	Identification and Validation of a New Set of Five Genes for Prediction of Risk in Early Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 9686-9702.	4.1	18
65	Body Mass Index and Prognosis of Metastatic Breast Cancer Patients Receiving First-Line Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1862-1867.	2.5	22
66	Exemestane for Breast Cancer Prevention: A Critical Shift?. <i>Cancer Discovery</i> , 2012, 2, 25-40.	9.4	23
67	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2593-2600.	1.6	218
68	A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2012, 5, 17.	3.0	1
69	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	1.3	79
70	Whither the PET Scan? The Role of PET Imaging in the Staging and Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2012, 14, 20-26.	4.0	3
71	Anthracyclines in the management of metastatic breast cancer: state of the art. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 11-15.	2.2	3
72	Case histories: breast cancer. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 36-42.	2.2	0

#	ARTICLE	IF	CITATIONS
73	Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review. <i>Tumori</i> , 2011, 97, 690-692.	1.1	16
74	The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. <i>Breast</i> , 2011, 20, S36-S41.	2.2	19
75	Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 2144-2149.	1.6	167
76	Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 229-232.	3.2	19
77	Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care. <i>Journal of Clinical Oncology</i> , 2011, 29, 7-10.	1.6	41
78	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15
79	Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. <i>Cancer Prevention Research</i> , 2010, 3, 1451-1461.	1.5	783
80	The Hypoxic Profile during Trekking to the Pyramid Laboratory. <i>High Altitude Medicine and Biology</i> , 2009, 10, 233-237.	0.9	11
81	Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 131-136.	2.5	12
82	New Understanding of the Role of Anthracyclines in Early-Stage Breast Cancer: Patient Selection Considerations. <i>Clinical Breast Cancer</i> , 2008, 8, S179-S183.	2.4	13
83	Relationship between individual ventilatory response and acute renal water excretion at high altitude. <i>Respiratory Physiology and Neurobiology</i> , 2008, 162, 103-108.	1.6	4
84	HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. <i>Journal of the National Cancer Institute</i> , 2008, 100, 14-20.	6.3	344
85	Metabolism: A Bottleneck in <i>In Vitro</i> Toxicological Test Development. <i>ATLA Alternatives To Laboratory Animals</i> , 2006, 34, 49-84.	1.0	161
86	Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3912-3918.	1.6	85
87	Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. <i>British Journal of Cancer</i> , 2005, 93, 406-411.	6.4	16
88	Survival of metastatic breast carcinoma patients over a 20-year period. <i>Cancer</i> , 2005, 104, 1742-1750.	4.1	253
89	Dendritic Cells as a Tool for the Predictive Identification of Skin Sensitisation Hazard. <i>ATLA Alternatives To Laboratory Animals</i> , 2005, 33, 47-62.	1.0	94
90	HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. <i>Bone Marrow Transplantation</i> , 2004, 34, 413-417.	2.4	10

#	ARTICLE	IF	CITATIONS
91	Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 31-35.	6.4	66
92	Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. <i>British Journal of Cancer</i> , 2004, 90, 962-967.	6.4	69
93	The Quality of Life Issue in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 223-224.	2.4	0
94	Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 919-927.	1.2	48
95	Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs. <i>Clinical Pharmacokinetics</i> , 2002, 41, 431-444.	3.5	168
96	Weekly Docetaxel/Paclitaxel in Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2002, 3, 346-352.	2.4	6
97	Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 508-518.	2.4	42
98	Pemetrexed: A promising new treatment for breast cancer. <i>Seminars in Oncology</i> , 2002, 29, 36-41.	2.2	92
99	Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 171-179.	2.5	82
100	Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 15-17.	2.2	0
101	Role of Epirubicin in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2000, 1, S46-S51.	2.4	29
102	Role of 2-[18F]-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) in the Early Assessment of Response to Chemotherapy in Metastatic Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2000, 1, 156-161.	2.4	90
103	Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors. <i>Journal of Clinical Oncology</i> , 1999, 17, 3596-3602.	1.6	89
104	Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia. <i>Annals of Oncology</i> , 1999, 10, S91-S94.	1.2	21
105	Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2510-2517.	1.6	89
106	Anthracyclines-paclitaxel combinations in the treatment of breast cancer. <i>Annals of Oncology</i> , 1997, 8, 939-943.	1.2	13
107	Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. <i>Annals of Oncology</i> , 1996, 7, 978-979.	1.2	40
108	Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study. <i>Annals of Oncology</i> , 1996, 7, 857-860.	1.2	13